The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies
Molecular Pharmaceutics · 02.12.2024 · 21 (12) · 5989-6006
DOI: 10.1021/acs.molpharmaceut.4c00325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 04.11.2024. Verfasst von Hao Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, People's Republic of China. Hauptthemen laut MEDLINE: Etomidate. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 180 Literaturangaben. Gefördert von: Health Commission of Sichuan Province, First People?s Hospital of Neijiang Southwest Medical University, Second People's Hospital of Neijiang, Southwest Medical University.
Abstract (Originalsprache)
Etomidate is a synthetic imidazole anesthetic that exerts hypnotic effects by potentiating the action of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) or directly activating the anionic GABA (GABAA) receptor. It stands out among many anesthetics because of its multiple advantages, such as good hemodynamic stability and minimal inhibition of spontaneous respiration. However, its low water solubility and side effects, such as adrenal cortex inhibition and myoclonus, have limited the clinical application of this drug. To address these issues, extensive research has been conducted on the drug delivery of etomidate in recent decades, which has led to the emergence of different etomidate preparations. Despite so many etomidate preparations, so far some of the toxic side effects have not yet been effectively addressed. Herein we discuss the pharmaceutical design of etomidate that may resolve the above problem. We also propose targeted strategies for future research on etomidate preparations and discuss the feasibility of different administration routes and dosage forms to expand the application of this drug. Through this review, we hope to draw more attention to the potential of etomidate and its application challenges and provide valuable insights into the development of new etomidate preparations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, People's Republic of China.
- Department of Pharmacy, Zigong First People's Hospital, Zigong, Sichuan 643000, People's Republic of China.
- Department of Anesthesiology, Second People's Hospital of Neijiang, Southwest Medical University, Neijiang, Sichuan 641000, People's Republic of China.
- Department of Anesthesiology, First People's Hospital of Neijiang, Neijiang, Sichuan 641099, People's Republic of China.
ORCID-Profile: Hao Liu
Förderung
- Health Commission of Sichuan Province
- First People?s Hospital of Neijiang Southwest Medical University
- Second People's Hospital of Neijiang, Southwest Medical University
- Horizontal Scientific Research Project of The First People?s Hospital of Neijiang
Zitieren
APA
Zhang, H., Wu, A., Nan, X., Yang, L., Zhang, D., Zhang, Z., & Liu, H. (2024). The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies. Molecular Pharmaceutics, 21(12), 5989-6006. https://doi.org/10.1021/acs.molpharmaceut.4c00325
Vancouver
Zhang H, Wu A, Nan X, Yang L, Zhang D, Zhang Z, et al. The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies. Molecular Pharmaceutics. 2024;21(12):5989-6006. doi:10.1021/acs.molpharmaceut.4c00325
BibTeX
@article{Zhang2024,
author = {Zhang, Hao and Wu, Ailing and Nan, Xichen and Yang, Luhan and Zhang, Dan and Zhang, Zhuo and Liu, Hao},
title = {The Application and Pharmaceutical Development of Etomidate: Challenges and Strategies},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {12},
pages = {5989--6006},
doi = {10.1021/acs.molpharmaceut.4c00325}
}
EUVIMED